What Was Approved?
On August 13, 2026, the FDA granted accelerated approval to Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj plus dexamethasone for certain adults with multiple myeloma.
Who Is This Treatment For?
The approval is for adults with multiple myeloma who have received at least one previous line of therapy that included:
- A proteasome inhibitor
- An immunomodulatory agent
This means Zenbexus is not intended as a first treatment for newly diagnosed patients.
What Is Multiple Myeloma?
Multiple myeloma is a cancer of plasma cells, a type of white blood cell found in the bone marrow.
The disease can affect bones, kidneys, blood counts, and the immune system.
How Does Zenbexus Work?
Iberdomide is an immune-modulating medicine.
It is designed to affect cancer cells while also influencing the immune system’s response against multiple myeloma.
For this indication, it is used as part of a combination treatment rather than by itself.
Why Is This Approval Important?
Multiple myeloma often requires several different treatments over time because the disease can return or become resistant to previous therapies.
The approval of Zenbexus provides another treatment option for patients whose disease has already been treated. FDA also lists Zenbexus among its novel drug approvals for 2026.
What Does “Accelerated Approval” Mean?
Accelerated approval allows the FDA to approve certain treatments for serious conditions based on evidence that is reasonably likely to predict clinical benefit.
Additional studies may still be required to confirm the treatment’s benefit.
What Should Patients Discuss With Their Healthcare Team?
Patients should discuss:
- Previous multiple myeloma treatments
- Other medications
- Possible side effects
- Infection risk
- Blood count monitoring
- Pregnancy precautions
- Whether this combination is appropriate for their specific disease
Bottom Line
Zenbexus (iberdomide) is a newly approved treatment option for certain adults with previously treated multiple myeloma.
It is used in combination with daratumumab, hyaluronidase-fihj, and dexamethasone and represents another option for patients who need treatment after prior therapy.
Sources
- U.S. Food and Drug Administration — FDA grants accelerated approval to iberdomide combination for multiple myeloma, August 13, 2026.
- U.S. Food and Drug Administration — Novel Drug Approvals for 2026.